Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE vs ALDOMET
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Articaine is an amide local anesthetic that blocks sodium ion channels in nerve cell membranes, preventing depolarization and conduction of nerve impulses. Epinephrine is a vasoconstrictor that prolongs the anesthetic effect by reducing local blood flow and systemic absorption.
Methyldopa is a centrally acting alpha-2 adrenergic agonist. Its active metabolite, alpha-methylnorepinephrine, stimulates presynaptic alpha-2 receptors in the central nervous system, reducing sympathetic outflow from the brainstem and decreasing peripheral vascular resistance, leading to lowered blood pressure.
Local infiltration anesthesia for dental procedures,Nerve block anesthesia for dental procedures
Hypertension (first-line in pregnancy-induced hypertension),Off-label: treatment of hypertensive crises
Adults: 1:100,000 epinephrine formulation (4% articaine) administered as a submucosal local infiltration or nerve block; maximum dose 7 mg/kg (0.175 m L/kg) per appointment, not to exceed 500 mg (12.5 m L). 1:200,000 epinephrine formulation may be used; maximum dose same.
250 mg orally twice daily, increased as needed every 2-3 days; usual maintenance 500 mg to 2 g/day in 2-4 divided doses; maximum 3 g/day.
Articaine: terminal half-life ~20 minutes (0.33 h) in plasma; clinical context: rapid elimination limits systemic toxicity. Epinephrine: short half-life ~2 minutes; clinical effect terminated by uptake and metabolism.
1.5–2 hours (terminal elimination half-life); clinical context: Renal impairment prolongs half-life (up to 4–6 hours in severe impairment), necessitating dose adjustment.
Articaine is primarily metabolized by plasma esterases (butyrylcholinesterase) to its inactive metabolite articainic acid. Epinephrine is metabolized by catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO).
Primarily hepatic metabolism via conjugation and O-methylation; also undergoes decarboxylation and deamination. Active metabolites include alpha-methyldopamine and alpha-methylnorepinephrine.
Articaine is primarily metabolized by plasma esterases; its inactive metabolite articainic acid is excreted renally (approximately 90% as metabolites, <2% unchanged). Epinephrine is metabolized by COMT and MAO; metabolites and small amounts unchanged are excreted in urine (~90% renal).
Renal: ~70% as unchanged drug and metabolites (sulfate conjugate, O-methylated derivatives); fecal/biliary: ~20%; <5% removed by hemodialysis.
Articaine: ~60–80% bound to plasma proteins (primarily albumin). Epinephrine: ~50% bound to plasma proteins (albumin and alpha-1-acid glycoprotein).
~10-20% bound to plasma proteins (primarily albumin).
Articaine: Vd ~1.0 L/kg (healthy adults); large Vd indicates extensive tissue distribution. Epinephrine: Vd ~0.2 L/kg (predominantly in circulation and tissues).
0.2–0.4 L/kg; clinical meaning: Moderate distribution, indicating limited extravascular penetration.
Not applicable for submucosal injection (100% bioavailable locally). Oral epinephrine has negligible bioavailability due to first-pass metabolism. For systemic effects, IV administration yields 100% bioavailability.
Oral: ~50% (range 25-60%) due to first-pass metabolism; IV: 100%.
No dosage adjustment required for mild-to-moderate renal impairment; use with caution in severe renal impairment (GFR <30 m L/min) due to potential accumulation of articaine metabolite; monitor for toxicity.
GFR >50 m L/min: no adjustment; GFR 10-50 m L/min: interval every 12-24 hours; GFR <10 m L/min: interval every 24-48 hours or 250 mg every 36-48 hours.
No specific guidelines; use with caution in severe hepatic impairment (Child-Pugh C) due to reduced metabolism; consider reduced doses and monitor for prolonged effects.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use or reduce dose by 75%.
Children ≥4 years: 4% articaine with 1:100,000 or 1:200,000 epinephrine; submucosal local infiltration or nerve block; maximum dose 7 mg/kg (0.175 m L/kg) per appointment, not to exceed 7 mg/kg (absolute max 500 mg). For 1:100,000 formulation, maximum epinephrine dose 0.001 mg/kg (0.001 m L/kg) per injection.
10 mg/kg/day orally in 2-4 divided doses, increased gradually; maximum 65 mg/kg/day or 3 g/day.
No specific dose adjustment; consider reduced doses due to age-related decreased hepatic and renal function; monitor for prolonged anesthesia and cardiovascular effects; use lowest effective dose.
Initial dose 250 mg once or twice daily; increase slowly; monitor for hypotension, sedation, and bradycardia; avoid in patients with pre-existing bradycardia or heart block.
Not available
None
Risk of methemoglobinemia, especially in patients with glucose-6-phosphate dehydrogenase deficiency or hemoglobin abnormalities,Use with caution in patients with cardiovascular disease, hypertension, or hyperthyroidism due to epinephrine component,Avoid intravascular injection; may cause systemic toxicity or cardiovascular collapse,Caution in patients with hepatic or renal impairment,May cause allergic reactions or hypersensitivity; cross-sensitivity with other amide anesthetics is possible
Hepatic toxicity (fatal hepatic necrosis reported); hemolytic anemia (positive Coombs test common, may indicate hemolysis); sedation/drowsiness (impair mental alertness); orthostatic hypotension; caution in renal impairment (dose adjustment required); may cause positive direct Coombs test, which interferes with crossmatching; possible rebound hypertension upon abrupt discontinuation.
Hypersensitivity to articaine, epinephrine, or any component of the formulation,Hypersensitivity to amide-type local anesthetics,Patients with severe uncontrolled hypertension or hyperthyroidism,Patients with known sulfite sensitivity (epinephrine contains sodium metabisulfite),Do not use in patients with paroxysmal tachycardia or other serious arrhythmias
Active hepatic disease (acute hepatitis, cirrhosis); prior methyldopa-induced hepatic dysfunction; concurrent MAO inhibitor therapy; hypersensitivity to methyldopa; pheochromocytoma.
No known food-drug interactions. Avoid eating until numbness resolves to prevent oral trauma.
Avoid excessive sodium intake, as it can counteract the antihypertensive effect. No specific food interactions reported, but alcohol may potentiate hypotension and sedation. Iron supplements may reduce absorption of methyldopa; separate administration by at least 2 hours.
FDA Pregnancy Category C. No well-controlled studies in pregnant women. In animal studies, articaine and epinephrine have not shown teratogenic effects at clinically relevant doses. Risk to fetus cannot be ruled out. Use only if clearly needed. No specific trimester-associated risks identified; however, epinephrine may reduce uteroplacental blood flow, particularly if given with vasoconstrictors or during second/third trimester.
First trimester: No increased risk of major congenital malformations reported in human studies based on limited data. Second and third trimesters: No known teratogenicity; use for management of chronic hypertension in pregnancy is common, but consider potential for reduced placental perfusion if maternal blood pressure is excessively lowered.
Articaine and epinephrine are excreted into breast milk in low amounts. M/P ratio not available. The American Academy of Pediatrics considers articaine compatible with breastfeeding. However, theoretical risk of cardiovascular effects in infant exists. Use with caution, and advise mother to pump and discard milk for 4-6 hours after administration to minimize exposure.
Methyldopa is excreted into breast milk in small amounts (M/P ratio approximately 0.2-0.5). At typical maternal doses, infant exposure is likely subtherapeutic and considered compatible with breastfeeding. Monitor infant for potential hypotension or sedation.
No specific dose adjustment required based on pharmacokinetic changes in pregnancy. However, due to increased plasma volume and cardiac output, higher doses may be needed to achieve adequate anesthesia? Typically, lowest effective dose is recommended. Avoid excessive epinephrine (max 0.1 mg per appointment) to minimize risk of uteroplacental vasoconstriction.
Pregnancy may increase volume of distribution and renal clearance, potentially reducing methyldopa plasma concentrations. Dose adjustments may be necessary to maintain blood pressure control; monitor and titrate based on maternal blood pressure response. Typical starting dose: 250 mg orally twice daily; maximum up to 3 g/day in divided doses, but lower doses are often effective.
Aspirate before injection to prevent intravascular administration. Maximum dose: 7 mg/kg articaine (0.175 m L/kg of 4% solution with 1:100,000 epinephrine). Avoid in patients with hepatic porphyria. Use with caution in patients with sulfite allergy (epinephrine component contains sodium metabisulfite).
ALDOMET (methyldopa) is a centrally acting alpha-2 agonist used primarily for hypertension in pregnancy. Monitor for positive direct Coombs test, which can occur in up to 20% of patients on long-term therapy; this may interfere with cross-matching but rarely causes hemolysis. Hepatic adverse effects, including increased liver enzymes and rarely hepatitis, require monitoring. Sedation and dizziness are common initially; titrate dose slowly. Methyldopa may cause orthostatic hypotension; advise patients to rise slowly. A paradoxical pressor response may occur if given with MAO inhibitors.
You may experience temporary numbness of the tongue, lips, or face; avoid eating or drinking until sensation returns to prevent biting yourself.,Do not drive or operate machinery for at least 2 hours after administration, or until numbness resolves.,Contact your dentist or doctor immediately if you experience chest pain, difficulty breathing, rapid heartbeat, or severe headache after injection.,Inform your healthcare provider if you have heart disease, high blood pressure, thyroid problems, or are taking MAO inhibitors or tricyclic antidepressants.
Take exactly as prescribed; do not skip doses or stop suddenly as this may cause rebound hypertension.,This medication may cause drowsiness, especially at start of therapy; avoid driving or operating machinery until you know how it affects you.,Rise slowly from sitting or lying positions to minimize dizziness or fainting.,Report any unexplained fever, fatigue, jaundice (yellowing of skin/eyes), or dark urine to your healthcare provider immediately, as these may indicate liver problems.,Notify your doctor if you experience persistent dry mouth, flu-like symptoms, or swelling in the legs.,Regular blood pressure monitoring is essential; keep a log of readings.,Avoid alcohol, as it can increase drowsiness and lower blood pressure further.,Inform all healthcare providers, including dentists, that you are taking this medication.,Do not take any other medications, including over-the-counter products, without consulting your doctor.
"The concurrent use of acepromazine, a phenothiazine neuroleptic with significant α1-adrenergic receptor antagonism, and articaine, an amide local anesthetic, may result in enhanced hypotensive and arrhythmogenic effects. Acepromazine-induced vasodilation and decreased peripheral resistance, combined with articaine's potential for myocardial depression and conduction disturbances, particularly in cases of inadvertent intravascular injection, can precipitate severe hypotension and ventricular arrhythmias. Additionally, phenothiazines can potentiate the central nervous system depressant effects of local anesthetics, increasing the risk of sedation and respiratory depression."
"Coadministration of articaine, an amide local anesthetic that inhibits voltage-gated sodium channels, and levomilnacipran, a serotonin-norepinephrine reuptake inhibitor (SNRI), may increase the risk of adverse cardiovascular effects, particularly hypertension and arrhythmias. The SNRI's enhancement of norepinephrine activity can potentiate sympathomimetic responses, while articaine's sodium channel blockade may exacerbate conduction abnormalities. This combination requires caution due to potential for additive cardiotoxicity."
"Dextropropoxyphene, a centrally acting opioid analgesic, may cause additive central nervous system depression and respiratory depression when combined with articaine, a local anesthetic. This interaction can lead to profound sedation, respiratory compromise, and increased risk of bradycardia and hypotension. Co-administration requires careful patient monitoring to prevent serious adverse outcomes, especially in elderly or debilitated patients."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE vs ALDOMET, answered by our medical review team.
ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE is a Alpha/Beta Agonist that works by Articaine is an amide local anesthetic that blocks sodium ion channels in nerve cell membranes, preventing depolarization and conduction of nerve impulses. Epinephrine is a vasoconstrictor that prolongs the anesthetic effect by reducing local blood flow and systemic absorption.. ALDOMET is a Central Alpha Agonist Antihypertensive that works by Methyldopa is a centrally acting alpha-2 adrenergic agonist. Its active metabolite, alpha-methylnorepinephrine, stimulates presynaptic alpha-2 receptors in the central nervous system, reducing sympathetic outflow from the brainstem and decreasing peripheral vascular resistance, leading to lowered blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE and ALDOMET depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE is: Adults: 1:100,000 epinephrine formulation (4% articaine) administered as a submucosal local infiltration or nerve block; maximum dose 7 mg/kg (0.175 m L/kg) per appointment, not to exceed 500 mg (12.5 m L). 1:200,000 epinephrine formulation may be used; maximum dose same.. The standard adult dose of ALDOMET is: 250 mg orally twice daily, increased as needed every 2-3 days; usual maintenance 500 mg to 2 g/day in 2-4 divided doses; maximum 3 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE and ALDOMET in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE is classified as Category A/B. FDA Pregnancy Category C. No well-controlled studies in pregnant women. In animal studies, articaine and epinephrine have not shown teratogenic effects at clinically relevant doses. ALDOMET is classified as Category C. First trimester: No increased risk of major congenital malformations reported in human studies based on limited data. Second and third trimesters: No known teratogenicity; use for . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.